Kymera Therapeutics will announce Phase 1b trial results for KT-621 on December 8, 2025, via video conference.
Quiver AI Summary
Kymera Therapeutics, Inc. will host a video conference call and webcast on December 8, 2025, at 8:00 a.m. ET to announce results from the BroADen Phase 1b clinical trial of KT-621, an oral STAT6 degrader for moderate to severe atopic dermatitis. A press release with results will be issued at 7:00 a.m. ET on the same day. KT-621, the first STAT6-directed drug in clinical evaluation, has shown promise in degrading STAT6 in patients, potentially benefiting over 130 million people with Type 2 inflammatory diseases. Kymera is advancing its clinical studies, including ongoing trials for KT-621 in atopic dermatitis and plans for upcoming trials in asthma. The company focuses on developing targeted protein degradation therapies to provide innovative treatments for patients. For more information, interested parties can visit Kymera's website.
Potential Positives
- Kymera Therapeutics will present results from the BroADen Phase 1b clinical trial of KT-621, a novel oral STAT6 degrader, which has the potential to transform treatment for millions suffering from Type 2 inflammatory diseases.
- The investigational drug KT-621 demonstrated complete STAT6 degradation and safety comparable to placebo in previous trials, indicating promising therapeutic potential.
- The ongoing Phase 2b trials for both atopic dermatitis and asthma could accelerate KT-621's development and facilitate future Phase 3 registration studies.
- Kymera Therapeutics has established itself as an innovative leader in the development of targeted protein degradation therapies, enhancing its reputation and attractiveness to investors and stakeholders.
Potential Negatives
- The press release does not provide any concrete data or outcomes from the upcoming Phase 1b clinical trial, leaving investors without critical information about KT-621's effectiveness or safety profile beyond what has previously been disclosed.
- The announcement of results is scheduled for a future date, which may lead to uncertainty and speculation in the market regarding the company's performance and product viability until then.
- The absence of any positive prescriptive information in the release on potential commercialization or market strategy for KT-621 could raise concerns about the future positioning of the product in a competitive biopharmaceutical landscape.
FAQ
What is the purpose of the video conference on December 8, 2025?
The video conference will announce results from the Phase 1b clinical trial of KT-621 for atopic dermatitis.
How can I join the live webcast of the announcement?
You can register for the webcast via the link provided or by visiting the "News and Events" section on Kymera's website.
What is KT-621 and its significance?
KT-621 is an investigational oral STAT6 degrader aimed at treating Type 2 inflammatory diseases, including atopic dermatitis.
When will data from the ongoing KT-621 Phase 2b trial be available?
Data from the KT-621 Phase 2b trial in atopic dermatitis is expected to be reported by mid-2027.
What potential does KT-621 hold for patients?
KT-621 has the potential to transform treatment for over 130 million patients suffering from various Type 2 diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$KYMR Insider Trading Activity
$KYMR insiders have traded $KYMR stock on the open market 17 times in the past 6 months. Of those trades, 5 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $KYMR stock by insiders over the last 6 months:
- BROS. ADVISORS LP BAKER has made 2 purchases buying 655,500 shares for an estimated $28,842,000 and 0 sales.
- PARTNERS L P/IL BVF has made 3 purchases buying 317,167 shares for an estimated $13,955,348 and 0 sales.
- BRUCE N. JACOBS (Chief Financial Officer) sold 79,220 shares for an estimated $3,961,380
- JARED GOLLOB (Chief Medical Officer) has made 0 purchases and 5 sales selling 62,690 shares for an estimated $3,846,093.
- NELLO MAINOLFI (Chief Executive Officer) has made 0 purchases and 4 sales selling 60,000 shares for an estimated $3,299,736.
- JEFFREY W. ALBERS sold 5,000 shares for an estimated $295,949
- ELENA RIDLOFF sold 4,500 shares for an estimated $225,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$KYMR Hedge Fund Activity
We have seen 121 institutional investors add shares of $KYMR stock to their portfolio, and 114 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,761,824 shares (-25.7%) from their portfolio in Q3 2025, for an estimated $99,719,238
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 908,597 shares (+110.9%) to their portfolio in Q3 2025, for an estimated $51,426,590
- HOLOCENE ADVISORS, LP added 840,333 shares (+inf%) to their portfolio in Q3 2025, for an estimated $47,562,847
- REDMILE GROUP, LLC removed 803,289 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $45,466,157
- ALYESKA INVESTMENT GROUP, L.P. added 565,091 shares (+1130.2%) to their portfolio in Q3 2025, for an estimated $31,984,150
- FEDERATED HERMES, INC. added 558,700 shares (+inf%) to their portfolio in Q3 2025, for an estimated $31,622,420
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 520,593 shares (+574.4%) to their portfolio in Q3 2025, for an estimated $29,465,563
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$KYMR Analyst Ratings
Wall Street analysts have issued reports on $KYMR in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 11/26/2025
- Guggenheim issued a "Buy" rating on 11/03/2025
- BTIG issued a "Buy" rating on 10/22/2025
- Mizuho issued a "Outperform" rating on 10/21/2025
- Oppenheimer issued a "Outperform" rating on 10/01/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/18/2025
- RBC Capital issued a "Outperform" rating on 09/16/2025
To track analyst ratings and price targets for $KYMR, check out Quiver Quantitative's $KYMR forecast page.
$KYMR Price Targets
Multiple analysts have issued price targets for $KYMR recently. We have seen 11 analysts offer price targets for $KYMR in the last 6 months, with a median target of $75.0.
Here are some recent targets:
- Srikripa Devarakonda from Truist Securities set a target price of $80.0 on 11/26/2025
- Etzer Darout from Barclays set a target price of $70.0 on 11/05/2025
- Andrew S. Fein from HC Wainwright & Co. set a target price of $84.0 on 11/05/2025
- Derek Archila from Wells Fargo set a target price of $69.0 on 11/05/2025
- Brad Canino from Guggenheim set a target price of $90.0 on 11/03/2025
- Jeet Mukherjee from BTIG set a target price of $75.0 on 10/22/2025
- Joseph Catanzaro from Mizuho set a target price of $81.0 on 10/21/2025
Full Release
Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025
WATERTOWN, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the BroADen Phase 1b clinical trial evaluating KT-621, its oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD) on Monday, December 8, 2025. A press release detailing the results will be issued at 7:00 a.m. ET, followed by a video conference call and webcast at 8:00 a.m. ET.
To join the video call or view the livestreamed webcast, please register via this link , or visit “ News and Events ” in the Investors section of the Company’s website at www.kymeratx.com . A replay of the webcast and copy of the presentation will be available following the event.
About KT-621
KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Type 2 inflammation. In the Phase 1 clinical study in healthy volunteers, KT-621 demonstrated complete STAT6 degradation in blood and skin following low daily oral doses, reductions of multiple disease relevant Type 2 biomarkers, and a safety profile undifferentiated from placebo. KT-621, the first STAT6-directed drug to enter clinical evaluation, has the potential to transform treatment paradigms for more than 130 million patients around the world, including children and adults, suffering from Type 2 diseases such as atopic dermatitis (AD), asthma, bullous pemphigoid (BP), chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), chronic spontaneous urticaria (CSU), and prurigo nodularis (PN), among others.
The Company’s KT-621 BROADEN2 Phase 2b trial in moderate to severe AD patients is ongoing, and patient dosing has commenced. Data is expected to be reported by mid-2027. The BREADTH Phase 2b trial in asthma is planned to start in the first quarter of 2026. These studies are intended to accelerate KT-621 development and enable dose selection for subsequent parallel Phase 3 registration studies across multiple Type 2 dermatology, gastroenterology and respiratory indications.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit
www.kymeratx.com
or follow us on
X
or
LinkedIn
.
Investor and Media Contact:
Justine Koenigsberg
Vice President, Investor Relations
[email protected]
[email protected]
857-285-5300
